CN1352391A - Novel anti-tumor medicine and its screening method and use - Google Patents
Novel anti-tumor medicine and its screening method and use Download PDFInfo
- Publication number
- CN1352391A CN1352391A CN 00137771 CN00137771A CN1352391A CN 1352391 A CN1352391 A CN 1352391A CN 00137771 CN00137771 CN 00137771 CN 00137771 A CN00137771 A CN 00137771A CN 1352391 A CN1352391 A CN 1352391A
- Authority
- CN
- China
- Prior art keywords
- erbb3
- cell
- erbb2
- antibody
- heterodimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 30
- 238000012216 screening Methods 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 7
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 45
- 210000004027 cell Anatomy 0.000 claims description 82
- 239000000833 heterodimer Substances 0.000 claims description 42
- 230000012010 growth Effects 0.000 claims description 29
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000004614 tumor growth Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 20
- 102000048238 Neuregulin-1 Human genes 0.000 description 19
- 108090000556 Neuregulin-1 Proteins 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 238000005859 coupling reaction Methods 0.000 description 16
- 230000008878 coupling Effects 0.000 description 15
- 238000010168 coupling process Methods 0.000 description 15
- 206010006187 Breast cancer Diseases 0.000 description 14
- 208000026310 Breast neoplasm Diseases 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 12
- 230000001419 dependent effect Effects 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 238000001890 transfection Methods 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 230000010261 cell growth Effects 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 10
- 238000001114 immunoprecipitation Methods 0.000 description 10
- 235000015097 nutrients Nutrition 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000001464 adherent effect Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 239000013613 expression plasmid Substances 0.000 description 6
- 239000000710 homodimer Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000002079 cooperative effect Effects 0.000 description 4
- 230000009036 growth inhibition Effects 0.000 description 4
- 238000011275 oncology therapy Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000010307 cell transformation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108050001049 Extracellular proteins Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000002306 biochemical method Methods 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000012930 cell culture fluid Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000000749 co-immunoprecipitation Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 150000002634 lipophilic molecules Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 101710153593 Albumin A Proteins 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 101150039808 Egfr gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229940123466 ErbB-3 antagonist Drugs 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000001948 isotopic labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention provides a method of screening anti-tumor medicine and a kind of anti-tumor medicine capable of inhibiting growth of tumor cell as well as a powerful and specific tumor cell inhibiting method.
Description
The present invention relates to immunology.More particularly, relate to the enzyme with ErbB, especially the ErbB2/ErbB3 heterodimer is as the method for effect target inhibition growth of tumour cell, the method for screening antineoplastic, and the antineoplastic that obtains thus.
Tumour disease is a kind of human dead principal disease that causes.It results from physiology cell proliferation out of control has influenced the body normal physiological condition, thereby produces serious pathological reaction, often causes death.Though spending great effort aspect research of tumour disease and the processing, tumour disease remains human main causes of death at present.The method of multiple processing tumour disease is arranged, comprise operation, radiotherapy and chemotherapy.Operation can not fully be driven away tumour cell among the patient body with radiotherapy, and chemotherapy combines the growth that generally is used to control tumour cell separately or with additive method.The common target of antitumoral compounds among the patient body is to prevent tumor cell proliferation or kill somatoblast.When compound during to the tumour cell toxigenicity, they also seriously influence those usually to the teleorganic proper splitting cell of people.Therefore, be exactly to seek a single-minded blocking-up of energy or kill tumor cell and the method that do not influence normal cell propagation to a main direction in the tumour disease research.Currently be starved of a kind of like this method of handling tumour disease patient.
ErbBS is a receptoroid protein tyrosine kinase, and the cell signal of ErbB mediation plays an important role in the cardiac function of embryonic development or adult.On cellular level, signal (Gassmann and Lemke, 1997 that the propagation of the receptor-mediated cell of ErbB, differentiation, migration and eucaryotic cell structure are reset; The ErbB member that four kinds of similar Tzahar and Yarden, 1988), are arranged: ErbB-1, ErbB2, ErbB3 and ErbB-4.EGF can discern and in conjunction with one of part of ErbB1.ErbB3 and ErbB4 also can be discerned by several bodies of accompanying, comprising Neuregulin-1 (NRG-1).So far, also do not find the part of ErbB2.Yet ErbB2 can form heterodimer with ErbB3 or ErbB-4, and the formation of this heterodimer is conclusive to the cell signal effect of NRG-1.
The discovery of studying in the body of doing with assignment of genes gene mapping experiment etc. proves that ErbB2, ErbB3 and ErbB-4 be (Meyer and Birchmeier, 1996 in the signal chains that NRG-1 activates; Gassmann etc., 1996; Lee etc., 1996; Erickson etc., 1997).
Except developmental role, be amplified in people's adenoma of people's ErbB2 through being everlasting dissimilar and overexpression.ErbB2 is considered to work as the part of heterodimer always.And this process originates in combining of NRG-1 and ErbB3 or ErbB4.This part has been considered to two fully independently receptors bind points: one has high-affinity to ErbB3 or ErbB-4, and another all has less but nonselective affinity to all ErbB members.Like this, when NRG-1 existed, the ErbB3 of cell surface or ErbB4 just formed heterodimer with ErbB2.ErbB3 more special because: 1) ErbB3 easily with ErbB2 formation heterodimer; 2) when ErbB2 and ErbB3 while transformant, can obtain higher conversion ratio; 3) ErbB3 is in tumour cell, often is accompanied by the expression of ErbB2 and expresses; 4) in the ErbB2 trangenic mice, ErbB3 is overexpression also.
The present inventor's systematic study ErbB member and the effect between them, disclosed the formation mechanism of heterodimer, and their effects in the tumour cell breeding, and potential purposes.
The object of the present invention is to provide a kind of method that suppresses the growth of tumour cell stronger, more single-mindedly.
The present invention also aims to provide a kind of method of screening antineoplastic.
The present invention also aims to provide a kind of antineoplastic, it can suppress the growth of tumour cell stronger, more single-mindedly.
The present application people finds that the expression of ErbB2 in cell can not promote the breeding of cell, and the cell that can suppress oncogene ras mediation on the contrary is to cancerous cell transformation.The inventor finds that also ErbB2/ErbB3 can form the heterodimer that does not rely on part NRG-1, and this dimerization physical efficiency stimulates the growth of tumour cell.Particularly, the inventor has found the effect of ErbB3 in tumour forms first.Based on above discovery, the inventor has imagined following technical scheme to realize purpose of the present invention.
The invention provides a kind of method of screening antineoplastic.Promptly cell and the candidate compound with coexpression ErbB2 and ErbB3 interacts.Described cell can be, for example use ErbB2 and the permanent cotransfection of ErbB3 expression vector and to the NIH3T3 of cancerous cell transformation cell, human tumor cells is BT-474 or SK-BR-3 human breast cancer cell.And not transfected and the NIH3T3 cell independent transfection of ErbB2, or the MCF-7 cell then is used to do negative control.The screening object is various possible organic or inorganic molecules.Usually should be water-soluble or lipophilic molecule.Solvent can be physiological saline, PBS, water etc.Lipophilic molecule can be dissolved in 100% alcohol or DMSO earlier, then is dissolved in the cell culture fluid again.Usually when alcohol or DMSO were added in the cell culture fluid processing cell, its dilutability was more than 1: 1000.And there is the growth of situation and/or cell and differentiation situation a index as the screening cancer therapy drug with the ErbB2/3 heterodimer.Can suppress the cell of ErbB2, ErbB3 cotransfection when any medicine of discovery and grow, and can not suppress NIH3T3 cell non-transfection or the single transfection of ErbB2, these medicines will be taken as and the interactional candidate of ErbB2/3 heterodimer.Can also be further with the direct effect of these medicines and ErbB2/3 heterodimer, and detect, thereby verified with the method for aforesaid co-immunoprecipitation of the application or covalent coupling.In a typical example, the object that is screened is the antibody of anti-ErbB3.In another kind of example, the object that screens is the various possible molecules that ErbB3 had affinity.
The present invention also provides the antineoplastic that obtains with screening technique of the present invention.In a typical case, described antineoplastic is the ErbB3 antagonist, especially ErbB3 antibody.In another typical case, described antineoplastic also comprises ErbB2 antibody.Beat allly be, when two kinds of antibody couplings, antagonistic effect do not take place not only, obtained desirable stack or cooperative effect on the contrary.Than typical case be, described ErbB3 antibody is commercially available H3.105.5, described ErbB2 antibody is commercially available N12 (available from NEO MARKER company).
The invention provides a kind of method that suppresses growth of tumour cell, it comprises the formation that suppresses the ErbB2/ErbB3 heterodimer.One of mode that realizes described inhibition is to handle cell with the ErbB2/ErbB3 heterodimer antagonist of effective dose.Described antagonist is selected from the molecule that affinity is arranged with ErbB2 or ErbB3, and they can block, disturb or change the formation or the structure of ErbB2/ErbB3 heterodimer, thereby suppresses the growth of cell.Described antagonist is antibody for example, antibody fragment.Wherein be typically, described antagonist is the antibody in anti-ErbB3 extracellular protein zone or the antibody in anti-ErbB extracellular protein zone.Special character of the present invention is that the present invention finds that first ErbB3 antibody has the effect that suppresses growth of tumour cell by the formation that suppresses the ErbB2/ErbB3 heterodimer.Described effective dose depends on target cell, multiple factor such as used antagonist, and those skilled in the art can determine this amount by conventional test.
Tumour cell of the present invention can be people's a breast cancer cell.
Past thinks that always the independent high expressed of ErbB2 just can be carcinogenic.But the present invention confirms that ErbB2 does not have the function of stimulating cellular growth separately, and ErbB2 and ErbB3 form heterodimer in non-ligand-dependent mode, and this heterodimer is relevant with growth of tumour cell.Thus, the inventor draws the mechanism that a kind of new antitumor cell is grown.Particularly, the present invention first ErbB3 be tumor suppression target molecule new except that ErbB2.Thus, the method for a series of new inhibition growth of tumour cell and new method for screening anticancer medicine have been drawn.
Anti-ErbB3 antibody (H3.105.5) past that is used to study has been found the not influence (NeoMarks Catalogue, 1999) of growth of tumour cell to expressing ErbB3.Be different from research in the past, we have tested 5 people's breast tumor cell line: MCF-7, T47D, SK-BR-3, MDA-MB-453 and BT474.The cell of latter two cell line and ErbB3 antibody are done the time spent separately, and the speed of growth is suppressed.What is interesting is that SK-BR-3 cell and ErbB3 antibody effect separately are not remarkable, and demonstrate ErbB2 and the big 2.5 times reactivity of ErbB3 antibody conjugates comparison ErbB2 antibody.When two kinds of antibody use simultaneously, anti-ErbB antibody can be reduced by at least five times, but still can obtain the effect that antitumor cell is grown, its threshold is suitable with the independent maximum effect value of anti-ErbB antibody of using, and because of ErbB2 is expressed among the cardiac muscle cell, anti-ErbB antibody is applied in and causes 28% patient that heart failure takes place among the patient.And ErbB3 there is no expression in cardiac muscle, therefore the use of anti-ErbB3 antibody or and being used in combination of anti-ErbB antibody, make the use amount of anti-ErbB antibody reduce, can both reduce the spinoff that produces heart failure in the tumour patient.
Fig. 1: during no part NRG-1, the Western trace of ErbB2, ERB3 immunoprecipitation separately or behind the cotransfection NIH 3T3.Among the figure, transfection: the independent transfection of 2 expression ErbB2 expression plasmid pRC/CMV-ErbB2 coding total length people ErbB2 cDNA, the independent transfection of 3 expression ErbB3 expression plasmid pCMVneo-HER3,2/3 expression pRC/CMV-ErbB2 and pCMVneo-HER3 cotransfection, 2+3 are represented the potpourri of cell pyrolysis liquid after the above-mentioned independent transfection; NRG-1: "-" expression NRG-1 does not exist, and "+" expression exists; Immunoprecipitation: 2 expressions precipitate with ErbB2 antibody (NCL-CB11), 3 expressions ErbB3 antibody (NCL-PC11) precipitation; Up is the Western trace that carries out with anti-phosphotyrosine antibody (anti-PTry) (reorganization RC20:HRPO is available from Transduction Laboratories); Middle row is the Western trace that carries out with ErbB2 antibody (NCL-CB11); Descending is the Western trace that carries out with ErbB3 antibody (NCL-PC11).
Fig. 2: the Western trace that detects homodimer or heterodimer with e.Among the figure, covalent coupling: covalent coupling has been carried out in "+" expression, and covalent coupling is not carried out in "-" expression.
Fig. 3: detect interior ErbB2 of tumour cell and ErbB3 form heterodimer in non-ligand dependent mode Western trace.
Fig. 4: a) the Western trace that the ErbB2/ErbB3 heterodimer of non-ligand dependent combines with signaling molecule Shc in the detection ErbB2/ErbB3 cotransfection NIH3T3 cell; B) the Western trace that the ErbB2/ErbB3 heterodimer of non-ligand dependent combines with signaling molecule She in the NIH3T3 tumour cell of ErbB2/ErbB3 coexpression.Anti--SHC represent with anti--Shc (C20) carry out the Western trace.
Fig. 5: a) common how anti-IgG of mouse and ErbB3 antibody H3.105.5 suppress the microscope inspection comparison of non-adhere-wall culture BT-474 human breast cancer cell growth.B) amount effect curve of common how anti-IgG of mouse and ErbB3 antibody H3.105.5 inhibition adhere-wall culture BT-474 human breast cancer cell growth relatively.Wherein, horizontal ordinate is represented antibody concentration, and ordinate is for suppressing number percent.
Fig. 6: do not have under the part NRG-1 condition, anti-ErbB antibody and anti-ErbB3 antibody list usefulness and coupling are to the inhibition of human breast carcinoma growth of tumour cell.Horizontal ordinate is that used antibody: IgG represents the common how anti-IgG of mouse (5 μ g/ml), ErbB2 represents the single usefulness of anti-ErbB antibody N12, ErbB3 represents that ErbB3 antibody H3.105.5 is single with (5 μ g/ml), and ErbB2/3 represents N12 and H3.105.5 coupling (concentration of two kinds of antibody all is 2.5 μ g/ml).Ordinate is the absorbance at 495nm place.Above the Nogata post is the inhibition number percent of the common how anti-IgG of relative mouse, and the display error line.
Fig. 7: anti-ErbB antibody and the coupling of anti-ErbB3 antibody are to the inhibition of human breast carcinoma growth of tumour cell.Horizontal ordinate is represented used antibody, and anti-ErbB antibody is N12 (50ng/ml); Anti-ErbB3 antibody is H3.105.5 (2.5 μ g/ml).Ordinate is cell growth indexes (absorbance at 495nm place).
Embodiment
Material
NIH 3T3 cell and breast tumor cell strain SK-BR-3, MDA-MB-453 and BT-474 are available from AmericanType Culture Collection.The LipofectAMINETM transfection reagent is available from Life Technologies, Inc..ErbB2 expression plasmid pRC/CMV-ErbB2 coding total length people ErbB2 cDNA, ErbB3 expression plasmid pCMVneo-HER3 coding total length people ErbB3 cDNA, from Drs Rodney Fiddes and Roger Daly (The Garvan Institute ofMedical Research, Darlinghurst, NSW 2010, Australia).NRG1 and be used for the ErbB2 antibody N12 of antitumor cell growth and ErbB3 antibody H3.105.5 available from NEO MARKER company.Connecting reagent BS3 obtains from PIERCE Chemical Company.The antibody (NCL-CB11) of anti-ErbB that is used for the test of immunoprecipitation and Western trace is available from Novocastra Laboratories Ltd..Anti--ErbB3 (NCL-PC11) is available from Santa CruzBiotechnology.Anti--Shc antibody (C-20) is available from Santa Cruz Biotechnology, and anti--phosphorylated tyrosine (reorganization RC20:HRPO) is available from Transduction Laboratories.The protease inhibitors completely that is used for lysis and immunoprecipitation is available from Boehringer Mannheim.Chemiluminescence agent (ECL) agent of second antibody that horseradish peroxidase-a flat iron plate for making cakes closes and reinforcement is available from NEN Life Science Products.ErbB2 and ErbB3 form heterodimer in non-ligand dependent mode
In order to study under the condition that does not have part NRG-1, the interaction of ErbB2 and ErbB3, the inventor carries out the transient expression of ErbB2 and/or ErbB3 with the low NIH3 cell (available from American Type Culture Collection) of expressing and not expressing ErbB3 of ErbB2.
37 ℃ in NIH 3T3 cell, 5%CO
2Maintain under the condition in the improved Eagle nutrient culture media of Dulbecco (DMEM) (add 10% calf serum (FBS) and select microbiotic (100 μ g/ml penicillin and streptomysin)).With reference to illustrating with LipofectAMINETM reagent (available from Life Technologies, Inc.) with ErbB2 expression plasmid pRC/CMV-ErbB2 and ErbB3 expression plasmid pCMVneo-HER3 difference or cotransfection NIH 3T3.The NRG-1 activity that may exist in the serum, cell is then got a cotransfection cell sample and was kept in the DMEM that adds 0.1%FBS hungry 18 hours being cultured in serum-free DMEM nutrient culture media 24 hours after the transfection, uses 10 then
-9M NRG-1 (available from NEO MARKER company) handled 10 minutes.
Gather in the crops whole cells transfected (1-2 * 10
6) with cold PBS washing and be dissolved in the 1ml ice crack and separate in the damping fluid (50mMTris[pH7.4], 5mM EGTA, 150mM NaCl, 1%Triton X-100, the 2mM sodium orthovanadate, the 50mM sodium fluoride, 2mM phenyl methyl sulfuryl fluoride, mixing protease suppresses sheet).The cytolysis thing was hatched 60 minutes at 4 ℃ with anti-ErbB antibody (NCL-CB11) or ErbB3 antibody (NCL-PC11).Immune complex is collected and is washed four times with lysis buffer with albumin A or Protein G Sepharose.
Carry out the Western trace test of immunoprecipitation then.The albumen of immunoprecipitation is with the sample loading buffer dissolving of boiling and do SDS-PAGE (6%) electrophoresis.The albumen electricity consumption is transferred to pvdf membrane.With the PBS that contains 5% skim milk add 0.02%Tween 20 4 ℃ spend the night blocking-up after, film at room temperature uses specificity first antibody (NCL-CB11, NCL-PC11 or reorganization RC20:HRPO) to survey 60 minutes.Albumen manifests by the second antibody that the chemical illuminating reagent (NEN LifeScience Products) with a kind of reinforcement is connected with horseradish peroxidase.
The result as shown in Figure 1.Row the 3rd row have the ErbB2 antigen active among Fig. 1 in the precipitation of anti-ErbB3 Antibody Preparation.This is not an antibody cross reaction, because middle row the 5th row show that anti-ErbB3 antibody can not deposit E rbB2, perhaps, and shown in end ranks 1, can not be in conjunction with ErbB2.In like manner, anti-ErbB antibody can not be in conjunction with ErbB3 (middle ranks 2 and row 5).
For the compound that proves ErbB2 and ErbB3 is a heterodimer, the cell of independent or cotransfection is carried out the covalent coupling reaction.Cell after the transfection was cultivated 12 hours in serum-free DMEM nutrient culture media.Control cells was handled 10 minutes with the serum-free DMEM nutrient culture media that contains 50nMNRG-1 (Neo Markers) earlier.With PBS washed cell three times, at room temperature use coupling agent BS then
3At 2mM/PBS, (PIERCE) the middle processing 30 minutes adds 10mM then, the Tris of pH7.5, and cessation reaction is 15 minutes under 0.9%NaCl and the 0.1 lysine solution room temperature.Gather in the crops as mentioned above then, cracking, immunoprecipitation.Immunoprecipitation carries out the test of Western trace behind the 4%SDS-PAGE electrophoresis.
Among Fig. 1, comparison array 3 and row 4 as seen, the existence of part NRG-1 strengthens the formation of ErbB2/ErbB3 heterodimer.Up, shown in row 3 and the row 4, in the cell of ErbB2/ErbB3 coexpression, the residue of the tyrosine of two kinds of albumen is all by phosphorylation.Because the tyrosine kinase activity of ErbB3 disappearance, therefore, ErbB3 should be by the ErbB2 phosphorylation.ErbB2 and ErbB3 form heterodimer in non-ligand dependent mode in the tumour cell
In the tumour cell of ErbB2 high expressed, whether also exist the above-mentioned dimer that does not rely on part to form in order to test, personnel selection breast tumor cell line SK-BR-3, MDA-MB-453 and BT474 replace the NIH3T3 cell, in serum-free DMEM nutrient culture media, cultivated 24 hours earlier, carry out the test of immunoprecipitation and Western trace then respectively as previously mentioned.The result as shown in Figure 3, and is similar to row 4 to the row 3 among Fig. 1, has the ErbB2/ErbB3 heterodimer of non-ligand-dependent to form in the tumour cell, and the existence of part NRG-1 then significantly strengthens the formation of heterodimer.The ErbB2/ErbB3 heterodimer of non-ligand dependent combines with signaling molecule Shc
The dependent ErbB2/ErbB3 heterodimer of known ligand is known to be combined with cell signal molecule Shc, and whether the ErbB2/ErbB3 heterodimer that the inventor has detected non-ligand-dependent also combines with Shc.Rotaring copolymering NIH 3 T 3 cell was as previously mentioned cultivated in serum-free DMEM nutrient culture media after 12 hours, results, cracking and immunoprecipitation as previously mentioned, and carry out the Western trace with anti-ErbB3 antibody and anti-Shc antibody and test.
The results are shown in Figure 4, the 1 descending demonstration of Fig. 4 a row, the Shc subspecies of 52kDa are not in conjunction with the Erb3 homodimer, and among this figure, the Shc subspecies of 46kDa are because of being hidden and can not record by a kind of non-differential protein; Fig. 4 a row 2 and row 3 show that no matter whether NRG1 exists, Shc combines with the ErbB2/ErbB3 heterodimer.Fig. 4 b shows that in the tumour cell of ErbB2/ErbB3 coexpression, Shc also interacts with ErbB3, and this effect does not rely on part.By suppressing the growth that the ErbB2/ErbB3 heterodimer suppresses tumour cell
With ErbB3 is the growth that target molecule suppresses tumour cell
BT474 human breast cancer cell with anti-ErbB3 antibody treatment ErbB2/ErbB3 high expressed.Used antibody is H3.105.5 (available from NEO MARKER company), and this antibody never is in the news and suppresses the effect of growth of tumour cell.That contrast is used is the common how anti-IgG of mouse) (available from Sigma).In soft agar, carry out non-adherent growth inhibition test respectively, on 96 porocyte culture plates, carried out the adherent growth inhibition test.
In non-adherent growth inhibition test, detailed process: by the density of 5 * 104/ml the BT474 human breast cancer cell is inoculated into and contains in the 4% soft agar DMEM nutrient culture media.37 ℃, 5%CO
2Cultivate 24hr under the condition.How anti-the H3.105.5 and the mouse that add 5 μ g/ml in test and control sample respectively be common.Cultivated again 30 days.Carry out microscope inspection then.With cell proliferation reagent box (Cell Titre Aqueous Promega).The result is shown in Fig. 5 a: after the antibody treatment 30 days, the cell of handling with the common how anti-IgG of mouse grew up to very significantly cell mass; And the cell of handling with H3.105.5, its growth is significantly suppressed.
In the adherent growth inhibition test, the BT474 human breast cancer cell is inoculated on the 96 porocyte culture plates of the DMEM nutrient culture media that contains 10%PBS with the density of 3000-5000 cells/well.37 ℃, 5%CO
2Cultivate 16hr under the condition, make it adherent.The H3.105.5 and the common how anti-IgG of mouse that add 1-5 μ g/ml in test and control sample respectively continue to cultivate 5-14 days.By specification then, with the cell number of corresponding each concentration of Cell Titre Aqueous enumeration of Promega company, and curve plotting.The result is shown in Fig. 5 b: H3.105.5 also has the obvious suppression effect to the BT474 human breast cancer cell of adherent growth, and presents positively related dose dependent.
This shows, be the growth that target molecule can suppress tumour cell by the formation that suppresses the ErbB2/ErbB3 heterodimer with ErbB 3.Unite and use ErbB2 and ErbB3 antibody suppressing the effect of growth of tumour cell
The inventor has also tested to unite and has used ErbB2 and ErbB3 antibody to suppressing the effect of growth of tumour cell.Used tumour cell is BT474, SK-BR-3 and MDA-MB-453.As previously mentioned with the density of 2000 cells/well with cell inoculation on 96 porocyte culture plates of the DMEM nutrient culture media that contains 10%PBS, 37 ℃, 5%CO
2Cultivate about 16 hours under the condition to adherent, add antibody: the common how anti-IgG:5 μ of mouse g/ml, ErbB3 antibody H3.105.55 μ g/ml, ErbB2 antibody N12 (available from NEO MARKER company) 5 μ g/ml, each 2.5 μ g/ml of two antibody, the same terms was cultivated 14 days down.During this time, changed to contain the fresh culture of antibody in per 48 hours.Measure cell quantity with nonspecific cell proliferation reagent box (Promega).The result as shown in Figure 6, the coupling of two kinds of antibody all has the obvious suppression effect to 3 kinds of cells that tried.Wherein, the antibody coupling has the synergistic effect that suppresses growth to BT474 and MDA-MB-453; SK-BR-3 then had the synergy that suppresses growth.
Based on above result, inventor's imagination: if ErbB2 antibody and the coupling of ErbB3 antibody have cooperative effect.Then be low to moderate cell to inferior concentration when insensitive when the concentration of ErbB2 antibody, the stack of double antibody or cooperative effect still may show significantly overall inhibiting effect.For this reason, the inventor has carried out foregoing adhere-wall culture, antibody treatment and detection with the SK-BR-3 human tumor cells.Different is, coupling be 50ng/ml ErbB2 antibody (N12) and the ErbB3 antibody H3.105.5 of 2.5 μ g/ml.The result is as shown in Figure 7: cell suppresses all not obvious, but then be subjected to remarkable inhibition when the double antibody coupling when single two kinds of antibody with experimental concentration.This shows, because the short growth of tumour cell effect of ErbB2/ErbB3 heterodimer, except known ErbB2, ErbB3 also can be as the target molecule of known cancer cell growth.Can obtain the stack or the cooperative effect of short growth of tumour cell during at both antibody in coupling.Anticarcinogen screening technique based on the ErbB2/ErbB3 heterodimer
Based on above test findings, the inventor also provides a kind of new method of screening cancer therapy drug, and has obtained a series of new cancer therapy drugs really.
Screening to ErbB3 antibody
Material therefor in this screening system for ErbB2 and the permanent cotransfection of ErbB3 expression vector and to the NIH3T3 of cancerous cell transformation cell.Not transfectedly then be used to do negative control with the NIH3T3 cell independent transfection of ErbB2.The object that is screened is the antibody of anti-ErbB3, and various antibody dissolves among the PBS, then is dissolved in the cell that is used in the nutrient culture media handling in the cultivation.Cell should be cultivated in 96 porocyte culture plates, and cell density is 4000 cells in every hole.Cell is placed in 96 orifice plates and cultivated 24 hours earlier, makes it adherent, then adds the medicine of suffered screening, or solvent itself.Can not suppress the cell of ErbB2 cells transfected or untransfected if certain ErbB3 antibody capable suppresses the cell growth of ErbB2/3 cotransfection, then this antibody just might become the candidate of the antagonist of ERBB2/3 heterodimer.
Can also be further with the direct effect of these medicines and ErbB2/3 heterodimer, the method for aforesaid co-immunoprecipitation of available the application or covalent coupling detects.Nature ErbB3 antibody to the compatibility of ErbB3 and selectivity all the biochemical method of available routine identify.
Found that ErbB3 antibody H3.105.5 can be used as the active component of cancer therapy drug.
To the screening of the molecule of affinity being arranged with ErbB3
Determine the compatibility of these molecules to ErbB3, we can use biochemical method.Such as the affinity column made from ErbB3 albumen, any ErbB3 has the molecule of affinity can be attached on this post and is detected.Another kind method be if this molecular energy by isotope labeling.So just can be directly and the cell combination of ErbB2 transfection or ErbB2/3 cotransfection the molecule of this mark.In conjunction with intensity measure with the isotope exit dose of unit cell.If this molecular energy can not just illustrate that this molecule tool is to the specific affinity of ErbB3 in conjunction with the single cells transfected of ErbB2 in conjunction with the cell of ErbB2/3 cotransfection.These molecules just can be used to do aforesaid cell growth inhibiting test.Usually the medicine that goes out with above-mentioned screening system also will be used for doing the inhibition growth of human tumor cells.The typical human tumor cells relevant with ErbB3 is BT-474 and SK-BR-3 human breast cancer cell.As negative control, the MCF-7 cell also should be used for doing the cell growth inhibiting test.Method of being done experiment and aforementioned NIH3T3 test cell line are just the same.
Claims (7)
1. method of screening antineoplastic, it comprises:
Interact with cell of expressing ErbB2 and ErbB3 and candidate compound;
Detect the growth inhibited of cell;
The growth inhibited positive shows that candidate compound is an antineoplastic.
2. antineoplastic, it obtains with the described method screening of claim 1.
3. medicine according to claim 2, it comprises the anti-ErbB antibody and/or the anti-ErbB3 antibody of effective dose.
4. medicine according to claim 3, anti-ErbB antibody wherein comprises N12, described anti-ErbB3 antibody comprises H3.105.5.
5. cytostatic method, it is to react the formation that suppresses the ErbB2/ErbB3 heterodimer by the described medicine of claim 2 and ErbB2 and/or ErbB3.
6. method according to claim 1 or 5, wherein said cell comprises tumour cell.
7. method according to claim 8, wherein said cell comprises the human mammary tumour cell.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB00137771XA CN1151843C (en) | 2000-12-27 | 2000-12-27 | Novel anti-tumor medicine and its screening method and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB00137771XA CN1151843C (en) | 2000-12-27 | 2000-12-27 | Novel anti-tumor medicine and its screening method and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1352391A true CN1352391A (en) | 2002-06-05 |
| CN1151843C CN1151843C (en) | 2004-06-02 |
Family
ID=4597809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB00137771XA Expired - Lifetime CN1151843C (en) | 2000-12-27 | 2000-12-27 | Novel anti-tumor medicine and its screening method and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1151843C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101918844A (en) * | 2007-06-18 | 2010-12-15 | 米迪缪尼有限公司 | Express the Synergistic treatment of the cell of EPHA2 and ERBB2 |
| CN103611153A (en) * | 2013-12-16 | 2014-03-05 | 新乡医学院 | Use of neuregulin 1 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1715926B (en) * | 2004-07-02 | 2011-08-17 | 上海泽生科技开发有限公司 | Use of neuregulin mutant |
-
2000
- 2000-12-27 CN CNB00137771XA patent/CN1151843C/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101918844A (en) * | 2007-06-18 | 2010-12-15 | 米迪缪尼有限公司 | Express the Synergistic treatment of the cell of EPHA2 and ERBB2 |
| CN103611153A (en) * | 2013-12-16 | 2014-03-05 | 新乡医学院 | Use of neuregulin 1 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1151843C (en) | 2004-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pinkas‐Kramarski et al. | Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. | |
| Pinkas-Kramarski et al. | The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin | |
| Pinkas-Kramarski et al. | ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network | |
| Waterman et al. | The C‐terminus of the kinase‐defective neuregulin receptor ErbB‐3 confers mitogenic superiority and dictates endocytic routing | |
| Tilak et al. | Receptor tyrosine kinase signaling and targeting in glioblastoma multiforme | |
| Roskoski Jr | The ErbB/HER receptor protein-tyrosine kinases and cancer | |
| Jackson et al. | Blockade of epidermal growth factor-or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects | |
| Karunagaran et al. | ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. | |
| Gijsbers et al. | GCP-2/CXCL6 synergizes with other endothelial cell-derived chemokines in neutrophil mobilization and is associated with angiogenesis in gastrointestinal tumors | |
| Friesel et al. | Heparin-binding growth factor 1 stimulates tyrosine phosphorylation in NIH 3T3 cells | |
| CN1541109A (en) | Inhibitors of HER3 activity | |
| CN107586826B (en) | Method for determining activity of IL-5 or IL-5R α antibody by transgenic cell activity test method | |
| US20180105597A1 (en) | TGFbeta Receptor II Antibodies | |
| CN1151843C (en) | Novel anti-tumor medicine and its screening method and use | |
| JP6264685B2 (en) | Multikinase inhibitor, anticancer agent, antimetastasis agent, drug resistance inhibitor, pain inhibitor and antidiarrheal | |
| Steck et al. | Expression of epidermal growth factor receptor and associated glycoprotein on cultured human brain tumor cells | |
| CN113773368B (en) | FOXM1 antagonistic polypeptide and derivative and application thereof | |
| US20120263707A1 (en) | Broad Spectrum ErbB Ligand Binding Molecules and Methods for Preparing and Using Them | |
| Cui et al. | The role of IL-11 and IL-Ra in angiogenesis of breast cancer | |
| CN111138515B (en) | Anti-tumor small molecule polypeptide targeting FGFRs and application thereof | |
| KR100523328B1 (en) | G-CSF Exon 3-Deleted Nucleic Acid, Protein and Microarray, and Detection Method for the Deletion of G-CSF Exon 3 | |
| CN100359004C (en) | Natural killer cell for transgenic expression cell chemotactic factors | |
| CN105837665A (en) | Polypeptide with specificity inhibiting HB-EGF promoting tumor cell migration and infiltration | |
| US20150065575A1 (en) | S100A8/A9 as a Diagnostic Marker and a Therapeutic Target | |
| Hedayatizadeh-Omran et al. | VERO stable cell lines expressing full-length human epidermal growth factor receptors 2 and 3: platforms for subtractive phage display |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANGHAI CHAK-SANG SCIENCE AND TECHNOLOGY DEVELOP Free format text: FORMER OWNER: ZHOU MINGDONG Effective date: 20060519 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20060519 Address after: 201203, Shanghai Pudong Zhangjiang hi tech Development Zone, No. 328, blue sky road, block C, building 2 Patentee after: Zesheng Science and Technology Development Co., Ltd., Shanghai Address before: 200233 No. 4, building 500, Caobao Road, Shanghai Patentee before: Zhou Mingdong |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Effective date of registration: 20071017 Pledge (preservation): Pledge |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20101206 Granted publication date: 20040602 Pledgee: Shanghai Pudong science and Technology Investment Co., Ltd. Pledgor: Zesheng Science and Technology Development Co., Ltd., Shanghai Registration number: 2007310000399 |
|
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 201203 Shanghai Curie road in Pudong New Area Zhangjiang hi tech Park No. 68 Patentee after: Zesheng Science and Technology Development Co., Ltd., Shanghai Address before: 201203, Shanghai Pudong Zhangjiang hi tech Development Zone, No. 328, blue sky road, block C, building 2 Patentee before: Zesheng Science and Technology Development Co., Ltd., Shanghai |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 201203 Shanghai Curie road in Pudong New Area Zhangjiang hi tech Park No. 68 Patentee after: ZENSUN (SHANGHAI) SCI & TECH CO., LTD. Address before: 201203 Shanghai Curie road in Pudong New Area Zhangjiang hi tech Park No. 68 Patentee before: Zesheng Science and Technology Development Co., Ltd., Shanghai |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20040602 |